Jump to content

Positive Real World Evidence of Mahana IBS Presented at the American College of Gastroenterology (ACG) Annual 2023 Scientific Meeting - Business Wire


Health Reporter

Recommended Posts

Positive Real World Evidence of Mahana IBS Presented at the American College of Gastroenterology (ACG) Annual 2023 Scientific Meeting  Business Wire

 

Positive Real World Evidence of Mahana IBS Presented at the American College of Gastroenterology (ACG) Annual 2023 Scientific Meeting

Large, two-year data set analyzed by Mass General Hospital demonstrates that nearly 60% of users who completed the Mahana IBS program in the real world setting reported clinically meaningful reduction in severity of IBS symptoms.

SAN FRANCISCO--()--Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced compelling results from the analysis presented by Mythili Pathipati, M.D. of Mass General Hospital at ACG 2023 Scientific Meeting in Vancouver on October 24, 2023 demonstrating that nearly 60% of users who completed Mahana IBS in the real world setting reported clinically meaningful reduction in severity of IBS symptoms. The analysis also concluded that use of Mahana IBS significantly improved stress as measured by the Perceived Stress Scale (PSS) and highlighted key demographics for those subjects that would adhere and respond to Mahana IBS.

 

"The real world analysis performed by Dr. Pathipati, Dr. Staller and the Mass General Hospital team provides clear and compelling evidence that providers should consider incorporating Mahana IBS into their treatment algorithm,” said Darren Brenner, M.D., Northwestern University. “Having a new tool that’s been proven both in randomized controlled and now real world settings which can reduce pain, bloating and improve quality of life of our IBS patients across all subtypes without the risk of major side effects is truly transformative.”

The real world analysis evaluated results from 843 patients using Mahana IBS over a 2-year timeframe from August 2021 to August 2023. In addition to evaluating IBS symptom severity and anxiety, the real world analysis assessed factors associated with adherence and response to Mahana IBS.

“As someone living with IBS, this substantial Real World Evidence reinforcing effectiveness of Mahana IBS is an exciting development. It gives patients struggling with IBS the confidence and hope that Mahana IBS is a credible treatment option that can help them achieve better control of their symptoms and improve their overall quality of life, which will support further patient adoption and access,” said Jeffrey Roberts, Founder of World IBS Day and IBS Patient Support Group.

View the full article

Link to comment
Share on other sites

  • Jeffrey Roberts changed the title to Positive Real World Evidence of Mahana IBS Presented at the American College of Gastroenterology (ACG) Annual 2023 Scientific Meeting - Business Wire

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...